effect of dexamethasone on the dose of remifentanil during pancreatic extracorporeal shock wave lithotripsy: a randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078171

Enrollment

Unknown

Registered

2023-11-30

Start date

2023-12-01

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal stones

Interventions

DEX group:Dexamethasone 8mg was given before anesthesia induction

Control group:The same amount of normal sodium was given before anesthesia induction

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1)Age =18 and =65 years old; BMI 18 ~ 28 kg/m2; ASA class I-II 2) patients undergoing elective first pancreatic extracorporeal shock wave lithotripsy under intravenous anesthesia 3) Patients voluntarily participated and signed informed consent

Exclusion criteria

Exclusion criteria: 1) patients with predicted difficult airway, such as limited mouth opening, Mallampati score =3, etc. 2) patients with respiratory insufficiency or sleep apnea 3) patients with poorly controlled diabetes (glycosylated hemoglobin = 9.1%) and 4) allergy to the study narcotic drugs due to long-term use of painkillers

Design outcomes

Primary

Measure	Time frame
The median effective concentration of remifentanil;	—

Secondary

Measure	Time frame
Incidence of nausea, vomiting, pruritus and pain VAS score in PACU and 24 hours postoperatively;Respiratory-related adverse events;	—

Countries

CHINA

Contacts

Public ContactLi Bo

Shanghai Changhai Hospital

ishilibo@163.com+86 186 2185 2982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026